Q3 2025 AbbVie Inc Earnings Call Transcript
Key Points
- AbbVie Inc (ABBV) delivered strong financial results, with adjusted earnings per share of $1.86, exceeding guidance by $0.10.
- Total net revenues reached nearly $15.8 billion, reflecting high single-digit sales growth and surpassing expectations by approximately $300 million.
- The company raised its 2025 outlook for the third time this year, indicating positive momentum and confidence in future performance.
- Skyrizzy and Renvoc, leading immunology medicines, achieved combined sales growth of more than 40%, with neuroscience also showing double-digit revenue growth.
- AbbVie Inc (ABBV) continues to invest in its pipeline, with approximately 90 programs across all stages of development, and anticipates several important milestones over the next two years.
- Humira's global sales declined by 55.7% due to biosimilar competition, impacting overall revenue.
- The aesthetics segment faced challenging market conditions, with global sales down 4.2% and consumer sentiment remaining low due to economic concerns.
- Despite strong performance, the company faces continued headwinds from Humira erosion and IRA pricing impacts on Imbruvica.
- The aesthetics market, particularly in the US, is experiencing softness, affecting Botox and Juvederm sales.
- AbbVie Inc (ABBV) anticipates significant percentage erosion for Humira in the coming years, although the absolute dollar decline will diminish.
Good morning and thank you for standing by. Welcome to the every 3rd quarter 2025 earnings conference call. All participants will be able to listen-only until the question-and-answer portion of this call. You may ask a question by pressing one on your phone. Today's call is also being recorded. If you have any objections, you may disconnect it this time. I would like to introduce Ms. Lila Shay, senior Vice President in investor relations.
Thank you. You may begin.
Good morning and thanks for joining us. Also on the call with me today are Rob Mark Michael, Chairman and Chief Executive Officer, Jeff Stewart, executive Vice President, Chief Commercial Officer, Rupal Thacker, executive Vice President, Research and Development, Chief Scientific Officer, and Scott Rentz, executive Vice President, Chief Financial Officer.
Before we get started, I'll note that some statements we make today may be considered forward-looking statements based on our current expectations. Abby cautions that these forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
